hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06322745 id: 1986 briefTitle: Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy overallStatus: RECRUITING date: 2023-06-01 date: 2025-01-01 date: 2025-03-01 date: 2024-03-21 date: 2024-03-21 name: Al-Azhar University class: OTHER briefSummary: To compare the outcome of thulium beam coagulation versus suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy. conditions: Renal Tumor conditions: Renal Malignant Tumor studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A randomized prospective comparative study. Two-arm parallel assignment:
Second Arm: involves cases of laparoscopic partial nephrectomy using thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed. primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Suture renorrhaphy only for hemostasis of the tumor bed in laparoscopic partial nephrectomy name: Thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy measure: Intraoperative Warm Ischemia time (WIT) in minutes (time of renal artery clamping). measure: Suture time and operative time in minutes measure: Intraoperative number of sutures for renorraphy measure: Intraoperative Blood loss measure: Blood transfusion rate measure: Renal function: serum creatinine measure: Renal function: estimated GFR (eGFR) measure: Transforming growth factor beta (TGF-β) urine level measure: Monocyte chemoattractant protein (MCP-1) urine level measure: Hospital stay measure: Post operative pain sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Urology Department, Al-Azhar University Hospitals status: RECRUITING city: Cairo zip: 11511 country: Egypt name: Malakah Mohammed, Secretary role: CONTACT phone: +20225107222 email: urologydepartment@azhar.edu.eg lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06322732 id: APHP191125 briefTitle: Optimization of Routine Obstetric and Neonatal Care in the Management of Severe Perinatal Asphyxia in Term or Near-term Newborns: Analysis of Sub-optimal Care acronym: OptiNeoCare overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2025-09 date: 2025-09 date: 2024-03-21 date: 2024-04-15 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: The purpose of this study is to identify and analyze suboptimal perinatal (obstetric-pediatric) care in the occurrence and management of severe perinatal asphyxia or death of the newborn at or near term.
Frequency of optimal or non-optimal maternal and neonatal management of hypoxic-ischemic encephalopathy (AIE) or neonatal death related to severe perinatal asphyxia. conditions: Perinatal Asphyxia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 336 type: ESTIMATED measure: sub-optimal perinatal care measure: Frequency of suboptimal care measure: Relationship measure: Outcome measure: Characteristics of suboptimal care measure: Determinantes of suboptimal care measure: Ad-hoc survey sex: ALL maximumAge: 1 Month stdAges: CHILD hasResults: False
nctId: NCT06322706 id: ABSK021-105 briefTitle: A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021 overallStatus: NOT_YET_RECRUITING date: 2024-03-28 date: 2024-12-31 date: 2025-12-31 date: 2024-03-21 date: 2024-03-21 name: Abbisko Therapeutics Co, Ltd class: INDUSTRY briefSummary: Part A: a single-center, randomized, open-label, three-cycle study to evaluate the pharmacokinetic (PK) profile of different doses of ABSK021 Capsules and the effect of a high-fat meal on the pharmacokinetic profile of ABSK021 Capsules in healthy subjects Part B: a single-center, open-label, fixed-sequence study to evaluate the effect of multiple oral doses of Omeprazole Enteric-coated Tablets on the PK profile of ABSK021 Capsules in healthy subjects conditions: Healthy Subjects studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: ABSK021 name: Omeprazole measure: Cmax measure: tmax measure: AUC0-∞ measure: AUClast measure: AE measure: SAE measure: blood pressure measure: respiratory rate measure: ECG QT Interval measure: t1/2 measure: CL/F measure: Vz/F sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06322680 id: ZSPAC-03 briefTitle: Impact of External Drainage of the Main Pancreatic Duct and Common Bile Duct on Pancreatic Fistula Following Pancreaticoduodenectomy overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-06-01 date: 2027-02-01 date: 2024-03-21 date: 2024-03-21 name: Shanghai Zhongshan Hospital class: OTHER name: Huadong Hospital name: RenJi Hospital name: The First People's Hospital of Yunnan name: First Affiliated Hospital Xi'an Jiaotong University name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School briefSummary: Pancreaticoduodenectomy (PD) is the standard treatment for tumors of the pancreatic head, distal bile duct, duodenum, and ampulla of Vater. With advances in surgical experience and instrumentation, the mortality rate of PD has decreased to below 5% in high-volume pancreatic centers. However, the postoperative complication rate remains high at 25%-50%, limiting the development and application of PD.
The main postoperative complications of PD are postoperative pancreatic fistula (POPF), delayed gastric emptying (DGE), post-pancreatectomy hemorrhage (PPH), and biliary leakage (BL). POPF, BL, and the subsequent abdominal infection, PPH, etc. are the main causes of death during hospitalization. Even in large, relatively mature pancreatic centers, the incidence of POPF remains as high as 10%-40%. In recent years, various methods have been used to prevent and treat POPF and BL after PD, such as pancreatic duct stent external drainage and external biliary drainage.
To date, there have been many studies by domestic and foreign scholars on the advantages and disadvantages of biliary and pancreatic duct external drainage versus internal drainage in PD in terms of perioperative POPF incidence, mortality rate, etc., but the research results are not consistent. Overall, pancreatic duct stent external drainage is only recommended for patients with a high risk of pancreatic fistula during PD. Currently, there have been a few relevant studies exploring and verifying the preventive effect of pancreatic duct stent external drainage on pancreatic fistula in patients with high risk of pancreatic fistula. For example, a retrospective study of 98 patients with soft pancreatic parenchyma by Teruyuki Usub et al. found that there was no significant difference between groups with and without pancreatic duct stent in preventing pancreatic fistula. However, due to the low level of evidence, only a few risk factors such as pancreatic texture and pancreatic duct diameter were included, and the risk of POPF was not systematically evaluated. Further clinical exploration and verification are needed. In 2013, Mark P Callery et al. proposed a pancreatic fistula risk score (The fistula risk score, FRS) based on the pancreatic fistula standard defined by the International Pancreatic Fistula Study Group, which included pancreatic texture, pathological type, pancreatic duct diameter, and intraoperative blood loss. This model can be used to systematically and quantitatively evaluate the risk of POPF. Previous studies did not have a clear stratification for patients undergoing pancreatic duct stent external drainage, which may have included too many patients with a low risk of pancreatic fistula, resulting in inaccurate results. Therefore, it is necessary to re-evaluate the effectiveness of pancreatic duct stent external drainage in preventing clinically relevant pancreatic fistula based on stratification of pancreatic fistula risk and disease type. At the same time, pancreatic juice contains a variety of digestive enzymes, of which pancreatic lipase, trypsin, and chymotrypsin all need to be activated by bile to play a role in digesting and decomposing fat and protein. Theoretically, biliary and pancreatic juice diversion may be able to reduce the incidence of pancreatic fistula and its related complications in PD patients.
Thus, the investigators design the present study to evaluate the impact of main pancreatic duct and biliary duct external drainage on postoperative complication, especially POPF. conditions: Pancreaticoduodenectomy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective, Multicenter, Controlled, Superiority Trial primaryPurpose: TREATMENT masking: NONE count: 322 type: ESTIMATED name: Main pancreatic duct and biliary duct external drainage name: Main pancreatic duct and biliary duct internal drainage measure: The incidence of clinically relevant postoperative pancreatic fistula (B/C grade fistula) within 90 days after surgery measure: Surgical Complications: Incidence and grading of complications within 90 days after surgery measure: Surgical Complications: Clavien-Dindo classification measure: Surgical Complications: Mortality rate measure: Surgical Complications: reoperation rate measure: Surgical Complications: readmission rate measure: Surgical Complications: rate of digital subtraction angiography for postoperative pancreatic hemorrhage measure: Surgical Complications: Total cost of perioperative treatment measure: Surgical Complications: Length of hospital stay measure: Adjuvant treatment: Proportion of patients with delayed adjuvant treatment (≥12 weeks) due to complications such as pancreatic fistula after surgery measure: Adjuvant treatment: Interval between the start of adjuvant treatment and surgery measure: Long-term survival related to malignant tumors: Overall survival (OS) measure: Long-term survival related to malignant tumors: Disease-free survival (DFS) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhongshan Hospital city: Shanghai state: Shanghai zip: 200000 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06322667 id: BAN2401-J081-401 briefTitle: A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab overallStatus: RECRUITING date: 2023-12-22 date: 2027-12-31 date: 2027-12-31 date: 2024-03-21 date: 2024-03-21 name: Eisai Co., Ltd. class: INDUSTRY briefSummary: The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab. conditions: Alzheimer's Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 5000 type: ESTIMATED name: No Intervention measure: Number of Participants With Amyloid Related Imaging Abnormality-Oedema/Effusion (ARIA-E) and Amyloid Related Imaging Abnormality-Microhemorrhage and Hemosiderin Deposit, and Cerebellar Microhaemorrhage (ARIA-H) measure: Number of Participants With Interruption or Discontinuation of Lecanemab After Onset of ARIA measure: Number of Participants With Infusion Related Reaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Eisai trial site 2 status: RECRUITING city: Hiroshima country: Japan lat: 34.4 lon: 132.45 facility: Eisai trial site 3 status: RECRUITING city: Kyoto country: Japan lat: 35.02107 lon: 135.75385 facility: Eisai trial site 1 status: RECRUITING city: Tokyo country: Japan lat: 35.6895 lon: 139.69171 hasResults: False
nctId: NCT06322654 id: 2023/ABM/01/00004/P/02 briefTitle: A Head-to-head Study Comparing the Functional Value of Two Models of Robotically Assisted Rehabilitation in SMA (Spinal Muscular Atrophy) Patients acronym: SMArt overallStatus: RECRUITING date: 2023-12-21 date: 2027-03-31 date: 2027-07 date: 2024-03-21 date: 2024-03-21 name: Wiktor Dega University Orthopedic and Rehabilitation Hospital class: OTHER briefSummary: A head-to-head study comparing the functional value of two models of robotically assisted rehabilitation in patients with SMA. A single-center, randomized, single-blinded, comparative study of Robotically Assisted Verticalization versus Robotically Assisted Locomotion.
2. Comparison: Robotically Assisted Verticalization primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Patients and their parents will not be blinded by the nature of the therapeutic procedure used after random allocation to the treatment group. Study personnel will be divided into Blinded Team and Unblinded Team to ensure objectivity of the assessment of safety and effectiveness of both strategies. whoMasked: INVESTIGATOR count: 200 type: ESTIMATED name: Robotically Assisted Locomotion name: Robotically Assisted Verticalization measure: Clinical assessment of patients using Children's Hospital Of Philadelphia Infant Test Of Neuromuscular Disorders, Revised Upper Limb Module, Hammersmith Functional Motor Scale measure: Clinical assessment of patients using Balance test minimum 1 min., Self-walk test of at least 2 meters, 6-minute gait test, Up&Go test, 10 meters gait test, hip range of motion and muscle strength evaluation. measure: Functional assessment of patients using GMFM (Gross Motor Function Measure) scale measure: X-ray or ultrasound scan imaging assessment of the spine, hip joints and bone mineral density measure: Assessment of the quality of life of patients and their caregivers using Pediatric Quality of Life Inventory ver. 4.0 measure: Hospitalization during or between rehabilitations that take place each 6 months measure: Occurence of discomfort during therapy requiring abrupt interruption or significant modification measure: Number of fractures sex: ALL maximumAge: 21 Years stdAges: CHILD stdAges: ADULT facility: Wiktor Dega University Orthopedic and Rehabilitation Hospital status: RECRUITING city: Poznań zip: 61-545 country: Poland name: Marek Jóźwiak role: CONTACT phone: 696052475 phoneExt: +48 email: sma@orsk.pl name: Radosław Rutkowski role: CONTACT phone: 696052475 email: sma@orsk.pl lat: 52.40692 lon: 16.92993 hasResults: False
nctId: NCT06322641 id: DAS-8092 id: U1111-1303-3089 type: OTHER domain: World Health Organization (WHO) briefTitle: A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists overallStatus: ENROLLING_BY_INVITATION date: 2024-03-26 date: 2024-04-26 date: 2024-04-26 date: 2024-03-21 date: 2024-04-03 name: Novo Nordisk A/S class: INDUSTRY briefSummary: The purpose of this survey is to collect information for scientific research and to better understand the role of systemic inflammation in identification, treatment and management of patients with Atherosclerotic Cardiovascular Disease (ASCVD) and Chronic Kidney Disease (CKD) conditions: Atherosclerotic Cardiovascular Disease (ASCVD) conditions: Chronic Kidney Disease (CKD) conditions: Systemic Inflammation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 336 type: ESTIMATED name: No treatment given measure: Nephrologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: KJT Group, Inc. city: Rochester state: New York zip: 14623 country: United States lat: 43.15478 lon: -77.61556 hasResults: False
nctId: NCT06322628 id: VSA006-2001 briefTitle: A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-12 date: 2026-07 date: 2024-03-21 date: 2024-03-21 name: Visirna Therapeutics HK Limited class: INDUSTRY briefSummary: Human genetic studies have shown that loss of function (LOF) mutations in HSD17β13 gene have a protective effect on the progression of alcohol-related and non-alcohol-related liver diseases, such as NASH, without significant adverse phenotypes.
VSA006 is a siRNA drug targeting HSD17β13 mRNA in the liver and reduce the protein level of HSD17β13. Based on phase 1 study results in healthy volunteers and NASH/suspected NASH patients, this phase 2 study is designed to evaluate the efficacy, safety, PK profiles and immunogenicity of VSA006 in Chinese NASH patients. conditions: Nash studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: VSA006 name: Placebo measure: Percentage of Participants Achieving ≥ 1 Stage Improvement in Histological Fibrosis with no Worsening of NASH measure: Percentage of Participants Achieving NASH Improvement with no Worsening of Fibrosis measure: Compared with placebo, the percentage change in serum alanine aminotransferase (ALT) measure: Compared with placebo, the change in liver fat fraction from baseline and liver fat percentage change from baseline measure: Compared with placebo, the percentage of participants with a > 30% decrease in liver fat fraction from baseline measure: Compared with placebo, the change and percentage change in noninvasive markers of fibrosis from baseline: FIB-4, NAFLD fibrosis score, and AST/PLT ratio index (APRI) measure: Percentage of Participants Achieving NASH Resolution with no Worsening of Fibrosis measure: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and their correlation with VSA006 measure: Maximum observed concentration (Cmax) of VSA006 measure: Time of maximum concentration of VSA006 (Tmax) measure: Area under the concentration-time curve from time zero (pre-dose) to the last quantifiable concentration (AUC0-t) of VSA006 measure: anti-drug antibodies (ADAs) of VSA006 sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06322615 id: MC221001 id: NCI-2024-00538 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 23-004067 type: OTHER domain: Mayo Clinic Institutional Review Board id: MC221001 type: OTHER domain: Mayo Clinic in Rochester briefTitle: Acupressure for Reducing Anxiety in Patients Undergoing Chemotherapy overallStatus: RECRUITING date: 2023-08-08 date: 2025-12-31 date: 2025-12-31 date: 2024-03-21 date: 2024-04-23 name: Mayo Clinic class: OTHER briefSummary: This clinical trial evaluates whether acupressure is helpful to reduce anxiety related to chemotherapy. Anxiety is experienced by many patients with cancer. Anxiety can be related to chemotherapy and may contribute to other symptoms, such as nausea and poor quality of life. Some patients diagnosed with cancer express interest in non-medicinal ways to manage symptoms. Acupressure is a noninvasive intervention that can be used for many different symptoms. Acupressure is well tolerated with minimal reports of adverse reactions, making it a good choice for patients with cancer. This study may help researchers learn whether acupressure is useful for managing anxiety in patients undergoing chemotherapy. conditions: Hematopoietic and Lymphatic System Neoplasm conditions: Malignant Solid Neoplasm studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 30 type: ESTIMATED name: Acupressure Therapy name: Educational Intervention name: Electronic Health Record Review name: Questionnaire Administration measure: Number of patients approached about undergoing acupressure intervention (Feasibility) measure: Number of patients interested in the initial acupressure intervention in the chemotherapy unit (Feasibility) measure: Number of patients interested in the home acupressure intervention (Feasibility) measure: Time taken for each nurse-led acupressure intervention in the chemotherapy unit (Feasibility) measure: Patient-reported changes in acute anxiety sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Laura S. Rhee, D.O. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06322602 id: 23-009112 id: NCI-2024-01762 type: REGISTRY domain: CTRP (Clinical Trials Reporting Program) briefTitle: Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors overallStatus: RECRUITING date: 2024-02-28 date: 2029-03 date: 2029-03 date: 2024-03-21 date: 2024-03-26 name: Mayo Clinic class: OTHER briefSummary: This observational trial evaluates the use of Ommaya reservoir placed during a biopsy to collect biomarkers longitudinally in patients with brain tumor. A biomarker is a measurable indicator of the severity or presence of the disease state. An Ommaya reservoir is a small device that's implanted under the scalp. It allows the doctor to take samples of cerebrospinal fluid (CSF) in the future without doing a spinal tap. The identification of biomarkers in CSF is rapidly emerging as a promising minimally invasive approach for monitoring tumor growth and response to therapy. In the future, these biomarkers may be used to help determine what treatments could be most effective and how well a tumor has responded to prior therapy. Currently, limited long-term access to CSF has made it difficult for studies to learn if collecting CSF at different points in the treatment process is useful. Having an Ommaya reservoir placed during a biopsy may allow for longitudinal biomarker collection in patients with brain tumor. conditions: Brain Neoplasms studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 10 type: ESTIMATED name: Intracranial Catheter Placement name: Lumbar Puncture name: Biopsy name: Biospecimen Collection name: Computed Tomography measure: Feasibility of Ommaya reservoir placement measure: Utility of Ommaya reservoir sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Terry C. Burns, M.D., Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False